Oruka Therapeutics, Inc.
80.15USD
-1.0000 (-1.23%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ORKA.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.62▼ | -$0.51 | 1 | 7 |
| Next quarter | -$0.66▼ | -$0.53 | 1 | 8 |
| Current year | -$2.37▼ | -$2.04 | 1 | 8 |
| Next year | -$2.86▼ | -$2.49 | 3 | 6 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.5 | -$0.55 | -0.05 (-9.9%) |
| 2026-03-31 | -$0.54 | -$0.48 | +0.06 (+10.6%) |
| 2025-12-31 | -$0.62 | -$0.45 | +0.17 (+26.9%) |
| 2025-09-30 | -$0.52 | -$0.55 | -0.03 (-5.0%) |
59 ratings from 15 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| BTIG | Reiterated | Buy | $151 | Oct 19, 2026 |
| Wedbush | Reiterated | Outperform | $165 | Sep 24, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 24, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 3, 2026 |
| Guggenheim | Reiterated | Buy | $200 | Aug 11, 2026 |
| Wedbush | Reiterated | Outperform | $165 | Aug 11, 2026 |
| BTIG | Reiterated | Buy | $151 | Aug 11, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Aug 3, 2026 |
| BTIG | Reiterated | Buy | $151 | Jul 13, 2026 |
| UBS | Maintained | Buy | $100 $130 | Jul 1, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Jun 23, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | May 18, 2026 |
| BTIG | Reiterated | Buy | $151 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75 $120 | Apr 29, 2026 |
| UBS | Maintained | Buy | $75 $100 | Apr 28, 2026 |
| Barclays | Maintained | Overweight | $78 $160 | Apr 28, 2026 |
| BTIG | Maintained | Buy | $78 $151 | Apr 27, 2026 |
| Wedbush | Maintained | Outperform | $45 $85 | Apr 15, 2026 |
| Guggenheim | Reiterated | Buy | $125 | Apr 13, 2026 |
| BTIG | Maintained | Buy | $73 $78 | Apr 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40 $70 | Apr 13, 2026 |
| Guggenheim | Reiterated | Buy | $125 | Apr 9, 2026 |
| Barclays | Maintained | Overweight | $50 $78 | Apr 7, 2026 |
| UBS | Maintained | Buy | $50 $75 | Apr 6, 2026 |
| Guggenheim | Maintained | Buy | $60 $125 | Apr 6, 2026 |
125 filings from 14 insiders · 21 buy / 29 sell over 6m
Officers and directors of ORKA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Quinlan Paul TOfficer, General Counsel | ExerciseEmployee Warrant (right to buy) | 9.0k | — | — | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Sell | 3.0k | $79.49 | $238k | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Sell | 4.1k | $78.79 | $323k | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Sell | 1.0k | $77.20 | $77k | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Sell | 500 | $76.12 | $38k | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Sell | 400 | $74.90 | $30k | Oct 20, 2026 |
| Quinlan Paul TOfficer, General Counsel | Exercise | 9.0k | $7.80 | $70k | Oct 20, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | ExerciseEmployee Warrant (right to buy) | 3.5k | — | — | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | ExerciseEmployee Stock Option (right to buy) | 3.5k | — | — | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Sell | 200 | $77.71 | $16k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Sell | 700 | $76.67 | $54k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Sell | 1.4k | $75.48 | $106k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Sell | 1.8k | $74.69 | $138k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Sell | 2.9k | $73.89 | $211k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Exercise | 3.5k | $7.80 | $27k | Oct 15, 2026 |
| Goncalves JoanaOfficer, Chief Medical Officer | Exercise | 3.5k | $6.84 | $24k | Oct 15, 2026 |
| Agarwal ArjunOfficer, Senior Vice President, Finance | ExerciseEmployee Stock Option (right to buy) | 1.5k | — | — | Oct 12, 2026 |
| Agarwal ArjunOfficer, Senior Vice President, Finance | ExerciseEmployee Stock Option (right to buy) | 8.5k | — | — | Oct 12, 2026 |
| Agarwal ArjunOfficer, Senior Vice President, Finance | Sell | 200 | $82.83 | $17k | Oct 12, 2026 |
| Agarwal ArjunOfficer, Senior Vice President, Finance | Sell | 2.0k | $81.86 | $160k | Oct 12, 2026 |
No analyst notes on ORKA yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 1 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 2 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 3 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
Members whose judged calls on ORKA have played out most reliably.
No settled calls on ORKA yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice